Metabolic & Incretin Signaling
Analytical catalog of synthetic peptides targeting GLP-1, GIP, and beta-3 adrenergic receptors to investigate cellular glucose homeostasis and lipid oxidation cascades.
GLP-1R / GIPR modulation, cAMP signaling, hormone-sensitive lipase stimulation, adipose beta-3 receptor agonism.
Indexed Compounds in Metabolic & Incretin Signaling
Select a peptide to review molecular formulas, amino acid sequences, and verified commercial sourcing links.
AOD-9604
Advanced Obesity Drug 9604 (Tyr-hGH 177-191 Synthetic Fragment)AOD-9604 is a synthetic 16-amino-acid peptide fragment corresponding to the lipolytic C-terminus of human growth hormone (hGH 177-191) with an added N-terminal tyrosine residue. Studied for its capacity to stimulate beta-3 adrenergic lipolytic pathways without affecting insulin sensitivity or serum IGF-1 levels.
Tirzepatide
Glucose-Dependent Insulinotropic Polypeptide (GIP) / GLP-1 Dual AgonistTirzepatide is a 39-amino-acid synthetic peptide engineered with dual agonism at both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Investigated in extensive clinical trials and preclinical pharmacological assays for glucose homeostasis, lipolytic modulation, and pancreatic beta-cell insulin secretion.
Semaglutide
GLP-1 Receptor Agonist Modified PolypeptideSemaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist modified with an alpha-aminoisobutyric acid substitution and a C-18 fatty diacid spacer to facilitate non-covalent albumin binding. Characterized across human clinical trials for glucose regulation and neuro-endocrine appetite pathway interactions.
Cellular Signaling Mechanisms & In Vitro Cascades
Transmembrane Affinity
Selective binding to primary G-protein coupled receptors (GPCRs), receptor tyrosine kinases (RTKs), or ionotropic complexes initiating intracellular phosphorylation.
Second Messenger Activation
Cascade phosphorylation via MAP kinase, PI3K/Akt, or adenylate cyclase pathways, modulating cytosolic calcium levels and nuclear transcription factor recruitment.
Transcriptional Synthesis
Upregulation of specific mRNA transcripts for structural proteins, angiogenic mediators, or neurotrophins documented across in vitro and pre-clinical assays.
Peer-Reviewed PubMed Literature Index
Primary publications documenting the molecular kinetics and assays of compounds in this axis.
The Effects of Human GH and Its C-Terminal Fragment (AOD9604) on Lipid Metabolism
Heffernan M, Summers RJ, Thorburn A, Ogru E, et al.
Key Finding: Demonstrated direct stimulation of lipolysis and inhibition of lipogenesis without adverse glycemic perturbation.
Safety and tolerability of the hexadecapeptide AOD9604 in humans
Stier H, Vos E, Kenley D.
Key Finding: Reported absence of anti-GH antibodies or adverse glycemic disruption across randomized clinical cohorts evaluating tolerability endpoints.
AOD9604 enhances in vitro chondrogenic differentiation of mesenchymal stem cells
Kwon DR, Park GY, Lee SU.
Key Finding: Reported synergistic enhancement of proteoglycan and type II collagen deposition in cartilage defect models.
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, et al.
Key Finding: Quantified substantial mean percentage reduction in body weight across 72 weeks in a double-blind, randomized, controlled trial.
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frias JP, Davies MJ, Rosenstock J, Perez Manghi FC, et al.
Key Finding: Demonstrated superior non-inferiority and statistical superiority in glycemic reduction compared to selective GLP-1 receptor monotherapy.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding JPH, Batterham RL, Calanna S, Davies M, et al.
Key Finding: Documented 14.9% mean body weight reduction endpoint at week 68 in clinical trial cohorts alongside significant reductions in cardiometabolic risk markers.
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, et al.
Key Finding: Reported significant 26% lower rate of first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke.
Storage & Reconstitution Parameters for Metabolic & Incretin Signaling
Lyophilized peptides cataloged in this pathway should be preserved at -20°C in desiccated containment. Upon reconstitution with Bacteriostatic Water or sterile isotonic saline, maintain solutions at 2°C to 8°C. Avoid repetitive freeze-thaw cycles which induce mechanical shearing of tertiary amino acid conformations.
Explore Other Research Pathways
All PathwaysTissue Repair & Angiogenesis
Preclinical Cellular Migration & Extracellular Matrix Remodeling
Pathways DirectoryNeuropeptides & CNS Signaling
Neurotrophic Factor Expression & Monoamine Neurotransmission
Pathways DirectoryGrowth Hormone Secretagogues & GHRH
Pituitary Somatotroph Receptors & Ghrelin Signaling Pathways
Pathways DirectoryDermal & Extracellular Matrix
Copper Chelation & Fibroblast Procollagen Biosynthesis
Pathways DirectoryCellular Longevity & Mitochondrial Axis
Telomerase Transcription & Electron Transport Modulation